Stockreport

IBN Coverage: Clene's (NASDAQ: CLNN) CNM-Au8(R) Affects Key Biomarkers, Long-term Survival in ALS Trials [Yahoo! Finance]

Clene Inc.  (CLNN) 
PDF LOS ANGELES, CA - ( NewMediaWire ) - August 23, 2024 - Clene (NASDAQ: CLNN) , a late clinical-stage biopharmaceutical company focused on improving mitochondrial health [Read more]